Combining HD-tDCS and iTBS in Treating Negative Symptoms of Schizophrenia
NCT: NCT07680959 · ENROLLING_BY_INVITATION
Brief Summary
Dysfunction of the dorsolateral prefrontal cortex (DLPFC) is central to the persistence of negative symptoms in schizophrenia. Both HD-tDCS and iTBS targeting the left DLPFC have shown therapeutic benefit. This trial will test the hypothesis that combining HD-tDCS with iTBS yields additive efficacy.
Frequently Asked Questions
What is Combining HD-tDCS and iTBS in Treating Negative Symptoms of Schizophrenia?
Combining HD-tDCS and iTBS in Treating Negative Symptoms of Schizophrenia is a clinical trial registered under NCT07680959. Current status: ENROLLING_BY_INVITATION.
What is the status of NCT07680959?
The current status of NCT07680959 (Combining HD-tDCS and iTBS in Treating Negative Symptoms of Schizophrenia) is: ENROLLING_BY_INVITATION.
When did Combining HD-tDCS and iTBS in Treating Negative Symptoms of Schizophrenia start?
Combining HD-tDCS and iTBS in Treating Negative Symptoms of Schizophrenia started on 2024-05-06.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.